International Patent: ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO CD19, CD20 AND CD3, AND PHARMACEUTICAL USE THEREOF

GENEVA, July 18 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/071543) for “ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO CD19, CD20 AND CD3, AND PHARMACEUTICAL USE THEREOF”. With publication no. WO/2026/149513, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 16/46

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....